ArticleInternational journal of hematology2026
Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in body composition, particularly sarcopenia and adipose tissue remodeling, have prognostic implications in multiple myeloma (MM). This retrospective study evaluated the prognostic value of PET/CT-derived muscle indices and brown adipose tissue (BAT) activity in 75 MM patients aged ≥ 60 years treated between January 2023 and March 2025. Autologous stem cell transplantation (ASCT) was performed in 41.3% of patients. Median progression-free survival was 6.06 months, with a median follow-up of 25.70 months. ASCT was independently associated with improved overall survival (OR: 0.249, p = 0.060) and a reduced risk of final disease progression (OR: 0.260, p = 0.019). Higher Charlson Comorbidity Index scores independently predicted increased mortality (OR: 1.677, p = 0.017). Reduced skeletal muscle mass, particularly a lower pectoralis major index, was independently associated with disease progression (OR: 0.003, p = 0.012). Among ASCT recipients, higher BAT activity (SUVmean) showed a strong negative correlation with post-transplant progression-free survival (rho = -0.717, p < 0.05). PET/CT-based body composition analysis may provide additional prognostic value in MM.
Indexed as
Identifiers
41917308What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.